LGND
LIGAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$314.77
+0.40%Year over year
Reported trailing growth
- Revenue
- +1.0%
- EBITDA
- -19.5%
- EBIT
- +72.6%
- EPS
- +8.4%
- Free cash flow
- +195.1%
- Operating cash flow
- +185.7%
Forward estimates
Based on analyst estimates
- Revenue
- +37.7%
- EBITDA
- +292.1%
- EPS
- +322.3%
Three-year CAGR
- Revenue
- +11.0%
- EBITDA
- +33.4%
- EBIT
- +149.6%
- Net income
- +54.5%
- EPS
- +46.0%
- Free cash flow
- -25.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026